Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336033667> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2336033667 abstract "We have conducted a double-blind comparative study of flutamide and chlormadinone acetate (CMA) on patients with stage C or D prostatic cancer and with no prior experience of hormone therapy. This is believed to be the first such trial entered in the medical literature, fifty-four patients were randomly selected to undergo flutamide (p.o.) monotherapy at a daily dose of 375 mg, which was determined as the optimal dose in Japan in our previous phase II study. Forty-nine others were randomly selected to undergo CMA (p.o.) monotherapy at a daily dose of 100 mg, which is the most commonly used dosage in Japan for patients with prostatic cancer. Ultimately, 47 patients from the flutamide group and 40 patients from the CMA group were judged eligible, with efficacy being evaluated after 12 weeks of treatment. Similar objective responses were seen in both groups: 48.9% (95% confidence limits 34.1-63.9%) in the flutamide group, 45% (95% confidence limits 29.3-61.5%) in the CMA group. The response at each organ site was also similar between the groups. Serum prostatic specific antigen decreased by more than 50% of the abnormal pretreatment level in 87.5% of the flutamide group and in 85.7% of the CMA group. Serum luteinizing hormone, follicle-stimulating hormone, testosterone and 5 alpha-dihydrotestosterone decreased significantly in the CMA group, but increased significantly in the flutamide group. The serum testosterone level after 12 weeks of treatment was 0.955 +/- 0.13 ng/ml in the CMA group and 6.64 +/- 0.38 ng/ml in the flutamide group. The serum estradiol level also increased significantly in patients in the flutamide group. The serum prolactin level decreased significantly in the flutamide group, but increased significantly in the CMA group. Eight patients on flutamide manifested gynecomastia. Diarrhea and hepatic toxicity were observed in both groups, but only rarely, and were well tolerated. We have thus concluded that flutamide is as effective as CMA in maintaining libido and potency without decreasing testosterone levels." @default.
- W2336033667 created "2016-06-24" @default.
- W2336033667 creator A5017120161 @default.
- W2336033667 creator A5018343954 @default.
- W2336033667 creator A5056993350 @default.
- W2336033667 creator A5068203096 @default.
- W2336033667 creator A5087645106 @default.
- W2336033667 date "1993-06-01" @default.
- W2336033667 modified "2023-10-02" @default.
- W2336033667 title "A Randomized Phase II Trial of Flutamide <italic>vs</italic> Chlormadinone Acetate in Previously Untreated Advanced Prostatic Cancer" @default.
- W2336033667 doi "https://doi.org/10.1093/oxfordjournals.jjco.a039630" @default.
- W2336033667 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7688829" @default.
- W2336033667 hasPublicationYear "1993" @default.
- W2336033667 type Work @default.
- W2336033667 sameAs 2336033667 @default.
- W2336033667 citedByCount "3" @default.
- W2336033667 crossrefType "journal-article" @default.
- W2336033667 hasAuthorship W2336033667A5017120161 @default.
- W2336033667 hasAuthorship W2336033667A5018343954 @default.
- W2336033667 hasAuthorship W2336033667A5056993350 @default.
- W2336033667 hasAuthorship W2336033667A5068203096 @default.
- W2336033667 hasAuthorship W2336033667A5087645106 @default.
- W2336033667 hasConcept C121608353 @default.
- W2336033667 hasConcept C126322002 @default.
- W2336033667 hasConcept C126894567 @default.
- W2336033667 hasConcept C168563851 @default.
- W2336033667 hasConcept C2778313021 @default.
- W2336033667 hasConcept C2778575703 @default.
- W2336033667 hasConcept C2779279991 @default.
- W2336033667 hasConcept C2779322244 @default.
- W2336033667 hasConcept C2780146029 @default.
- W2336033667 hasConcept C2780192828 @default.
- W2336033667 hasConcept C2908647359 @default.
- W2336033667 hasConcept C2986740045 @default.
- W2336033667 hasConcept C61367390 @default.
- W2336033667 hasConcept C71315377 @default.
- W2336033667 hasConcept C71924100 @default.
- W2336033667 hasConcept C99454951 @default.
- W2336033667 hasConceptScore W2336033667C121608353 @default.
- W2336033667 hasConceptScore W2336033667C126322002 @default.
- W2336033667 hasConceptScore W2336033667C126894567 @default.
- W2336033667 hasConceptScore W2336033667C168563851 @default.
- W2336033667 hasConceptScore W2336033667C2778313021 @default.
- W2336033667 hasConceptScore W2336033667C2778575703 @default.
- W2336033667 hasConceptScore W2336033667C2779279991 @default.
- W2336033667 hasConceptScore W2336033667C2779322244 @default.
- W2336033667 hasConceptScore W2336033667C2780146029 @default.
- W2336033667 hasConceptScore W2336033667C2780192828 @default.
- W2336033667 hasConceptScore W2336033667C2908647359 @default.
- W2336033667 hasConceptScore W2336033667C2986740045 @default.
- W2336033667 hasConceptScore W2336033667C61367390 @default.
- W2336033667 hasConceptScore W2336033667C71315377 @default.
- W2336033667 hasConceptScore W2336033667C71924100 @default.
- W2336033667 hasConceptScore W2336033667C99454951 @default.
- W2336033667 hasLocation W23360336671 @default.
- W2336033667 hasLocation W23360336672 @default.
- W2336033667 hasOpenAccess W2336033667 @default.
- W2336033667 hasPrimaryLocation W23360336671 @default.
- W2336033667 hasRelatedWork W1604671744 @default.
- W2336033667 hasRelatedWork W1999564086 @default.
- W2336033667 hasRelatedWork W2013076326 @default.
- W2336033667 hasRelatedWork W2056489288 @default.
- W2336033667 hasRelatedWork W2059573184 @default.
- W2336033667 hasRelatedWork W2079566134 @default.
- W2336033667 hasRelatedWork W2134349385 @default.
- W2336033667 hasRelatedWork W2153035386 @default.
- W2336033667 hasRelatedWork W2336033667 @default.
- W2336033667 hasRelatedWork W75430235 @default.
- W2336033667 isParatext "false" @default.
- W2336033667 isRetracted "false" @default.
- W2336033667 magId "2336033667" @default.
- W2336033667 workType "article" @default.